Background: MALAT1, a highly conserved long non-coding RNA (lncRNA), acts as oncogene in multiple human cancers. Results: miR-101 and miR-217 can silence MALAT1 expression and then inhibit esophageal cancer proliferation, migration and invasion. Conclusion: Tumor suppressor miR-101 and miR-217 can negatively regulate MALAT1 expression. Significance: These data provide a new mechanism for MALAT1 regulation.

A computer-aided diagnosis (CAD) system based on mammograms enables early breast cancer detection, diagnosis, and treatment. However, the accuracy of the existing CAD systems remains unsatisfactory. This paper explores a breast CAD method based on feature fusion with convolutional neural network (CNN) deep features. First, we propose a mass detection method based on CNN deep features and unsupervised extreme learning machine (ELM) clustering. Second, we build a feature set fusing deep features, morphological features, texture features, and density features. Third, an ELM classifier is developed using the fused feature set to classify benign and malignant breast masses. Extensive experiments demonstrate the accuracy and efficiency of our proposed mass detection and breast cancer classification method. INDEX TERMS Mass detection, computer-aided diagnosis, deep learning, fusion feature, extreme learning machine.

No abstract

BackgroundPOEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome still has no standard treatment. On the basis that both POEMS syndrome and myeloma have an underlying plasma cell dyscrasia, anti-myeloma therapy can be expected to be useful for POEMS syndrome. Chimeric antigen receptor T (CAR-T) cells targeting B cell maturation antigen (BCMA) has been used in the treatment of relapsed and refractory multiple myeloma (RRMM). No POEMS syndrome cases treated with anti-BCMA CAR-T cells have been reported.Case presentationHere, we, for the first time, report a POEMS syndrome case treated with anti-BCMA CAR-T cells. A 49-year-old female with incapacitating POEMS syndrome that progressed on lenalidomide treatment was enrolled in a phase I study involving anti-BCMA CAR-T cells (ChiCTR-OPC-16009113). Another patient with RRMM who had undergone six prior lines treatments was also enrolled in the study. They received infusions of anti-BCMA CAR-T cells. Both patients achieved a stringent complete response. Complete remission persisted in the patient with POEMS syndrome and lasted for 7.6 months before a relapse in RRMM patient. Both patients had toxicity consistent with the grade 1 cytokine release syndrome.ConclusionsThis is the first report of treatment by anti-BCMA CAR-T cells in POEMS syndrome. Our findings demonstrate the anti-BCMA CAR-T cell treatment may be a feasible therapeutic option for patients with POEMS syndrome and RRMM who do not respond well to traditional therapies.Trial registrationChiCTR-OPC, ChiCTR-OPC-16009113. Registered 29 August 2016.Electronic supplementary materialThe online version of this article (10.1186/s13045-018-0672-7) contains supplementary material, which is available to authorized users.